As proof of clinical validity, two uPAR-targeted cancer imaging agents—one for PET/CT (Carlsen et al., 2022) and one for NIR (Andersen et al., 2025)—have already advanced to phase II clinical trials. This evidence concerns the gene PLAUR and cancer.